Implications of cardiovascular risk in patients with type 2 diabetes who have abnormal lipid profiles: Is lower enough?

Diabetes, Obesity and Metabolism

Volumn 2, Issue 5, 2000, Pages 263-270

  Garber, Alan J ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

CHD; Cholesterol; Diabetes

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; DILTIAZEM; FIBRIC ACID DERIVATIVE; FIBRINOGEN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PLASMINOGEN ACTIVATOR INHIBITOR; PRAVASTATIN; SIMVASTATIN; VERAPAMIL;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DRUG METABOLISM; DRUG SAFETY; DYSLIPIDEMIA; FATALITY; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; RHABDOMYOLYSIS; SYNDROME;

EID: 0034526252     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1326.2000.00100.x     Document Type: Article

References (60)

1. Heart disease and diabetes
2. Management of dyslipidemia in adults with diabetes
3. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
4. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men?
5. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
6. Does glycemic control of type II diabetes suffice to control diabetic dyslipidemia? A community perspective
7. Vascular disease and lipids in diabetes
8. Lipids, glucose intolerance and vascular disease: The Framingham Study
9. Dyslipidemia, morbidity, and mortality in non-insulin-dependent diabetes mellitus. Lipoproteins and coronary heart disease in non-insulin-dependent diabetes mellitus
10. Plasma lipids and diabetes mellitus in an adult community
11. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study
12. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes
13. Epidemiology of hyperglycemia and atherosclerosis
14. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk
15. Lipoprotein compositional abnormalities and insulin resistance in type II diabetic patients with mild hyperlipidemia
16. Subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes
17. Low-density lipoprotein subclass patterns and risk of myocardial infarction
18. Treatment of diabetes mellitus to reduce its chronic cardiovascular complications
19. Syndrome X: 6 years later
20. Fibrinogen and risk of cardiovascular disease: The Framingham Study
21. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature
22. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease
23. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1
24. Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and the use of surrogate end-points
25. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus
26. Diabetic and hypertensive heart disease
27. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
28. Hyperinsulinemia, insulin resistance, and hyperglycemia: Contributing factors in the pathogenesis of hypertension and atherosclerosis
29. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
30. Diabetes mellitus and coronary heart disease
31. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial
32. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
33. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
34. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
35. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
36. Improved survival, reduced major coronary events and fewer revascularizations in simvastatin-treated 4s patients with impaired fasting glucose
37. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
38. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analyses in the Cholesterol and Recurrent Events (CARE) Trial
39. Prevention of cardiovascular events, death with pravastatin in patients with coronary heart disease, a broad range of initial cholesterol levels
40. Effect of pravastatin on cardiovascular events in older patients, women, and diabetics: The prava-3 pooling project
41. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
42. The Lipid Research Clinics Coronary Primary Prevention Trial: Results of 6 years of post-trial follow-up
43. Management of dyslipidemia in adults with diabetes
44. Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia
45. Lovastatin/gemfibrozil myopathy: A clinical, histochemical, and ultrastructural study
46. Rhabdomyolysis associated with simvastatin-gemfibrozil therapy
47. Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil
48. Rhabdomyolysis after taking atorvastatin with gemfibrozil
49. Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy
50. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia
51. Pharmacokinetics of the combination of fluvastatin and gemfibrozil
52. Natural statins and stroke risk
53. The interaction of diltiazem with lovastatin and pravastatin
54. Verapamil significantly increases serum concentrations of simvastatin but not pravastatin
55. Increased β-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance
56. Gemfibrozil alone and in combination with lovastatin for treatment of hypertriglyceridemia in NIDDM